Login to Your Account



AACR Roundup


Thursday, November 17, 2011
• Curis Inc., of Lexington, Mass., reported preclinical data showing that CUDC-907, a small-molecule inhibitor designed to target both PI3K and HDAC, had broad activity in hematologic cancer models. The company said it anticipates filing an investigational new drug application during the first half of 2012.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription